New roles will be based at Iqvia’s East Point operation in Dublin.
Iqvia, a clinical research pioneer for the pharma industry, is to create 100 new jobs in Dublin.
Iqvia is the result of a massive $17.6bn merger in 2016 between Quintiles – which has had a presence in Dublin since 1990 – and IMS Health.
‘Ireland has a rich base of life sciences talent, is a great place to do business, and we look forward to continuing to grow our business here’
– MARTIN GIBLIN
Minister for Finance Paschal Donohoe, TD, welcomed the news. “Ireland’s pharma industry continues to grow and today’s announcement by Iqvia is another exciting development. Ireland’s ability to retain companies such as Iqvia is a testament to our attractive business environment, robust regulatory framework and skilled labour force.”
Rich life sciences heritage
The new roles at the company’s Dublin East Point Campus will consist of highly skilled, full-time jobs in the areas of clinical project management, data management, drug safety and biostatistics.
In particular, Iqvia is recruiting pharmacovigilance specialists across a variety of safety services, spanning both clinical trials and medicines safety. There will also be a number of opportunities available for life science graduates.
“Ireland is a strategically important location for Iqvia, and today’s announcement represents a significant step in increasing our capability to serve our pharma customers across Europe and the world,” said Martin Giblin, senior vice-president, global head of centralised monitoring services and country head of Iqvia in Ireland.
“Ireland has a rich base of life sciences talent, is a great place to do business, and we look forward to continuing to grow our business here.”
Recruitment is underway and the company expects the roles to be filled in the first half of 2019.
“The investment is a vote of confidence in the country and adds significantly to the expert cluster in biopharma and clinical research in Ireland,” said Tommy Fanning, head of biopharmaceuticals at IDA Ireland.
“Iqvia’s decision to build on its existing strong presence provides high-quality, challenging jobs which fit well with the future of the life sciences sector in Ireland,” Fanning added.
